Background: Glucocorticoids (GCs) are commonly used for long-term medication in immunosuppressive and anti-inflammatory therapy. However, the data describing gluco-and mineralo-corticoid (MC) properties of widely applied synthetic GCs are often based on diverse clinical observations and on a variety of in vitro tests under various conditions, which makes a quantitative comparison questionable. Method: We compared MC and GC properties of different steroids, often used in clinical practice, in the same in vitro test system (luciferase transactivation assay in CV-1 cells transfected with either hMR or hGRa expression vectors) complemented by a system to test the steroid binding affinities at the hMR (protein expression in T7-coupled rabbit reticulocyte lysate). Results and Conclusions: While the potency of a GC is increased by an 11-hydroxy group, both its potency and its selectivity are increased by the D1-dehydro-configuration and a hydrophobic residue in position 16 (16-methylene, 16a-methyl or 16b-methyl group). Almost ideal GCs in terms of missing MC effects, as defined by our in vitro assay, are therefore prednylidene, budesonide, beclomethasone and betamethasone. The MC potency of a steroid is increased by a 9a-or a 6a-fluoro substituent. A hydrophilic substituent in position 16 (like 16-hydroxylation in triamcinolone) decreases both MC and GC properties. As no substituent that leads to an isolated reduction of GC activity could be characterized in our experiments, 9a-fluorocortisol, the most frequently used steroid for MC substitution, seems to be the best choice of available steroids for this purpose.
Introduction
Glucocorticoids (GCs) are potent suppressors of the immune response, which makes them frequently used agents in long-term anti-inflammatory therapy (1 -3) . Besides their GC properties, all of these steroids possess mineralocorticoid (MC) properties causing unwanted side effects such as fluid-electrolyte imbalance and hypertension (4) . This is most likely due to the close structural relationship of the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR) (5) and their overlapping signalling pathways. Both receptors belong to the steroid receptor superfamily, a subgroup of the nuclear receptors. The first one also includes the androgen, progesterone and estrogen receptor, the latter the receptors for thyroid hormone, vitamin D and retinoic acids, and a large group of orphan receptors (5 -7). The physiological human ligands of the MR and the GR are aldosterone and cortisol respectively. In the absence of ligands, the MR and the GR are associated with a heteromeric complex containing hsp70, hsp90 and other chaperone molecules (8 -10) . After ligand binding, a conformational change and partial dissociation of the complex occur, followed by nuclear translocation (11, 12) . Within the nucleus, the ligand-activated receptors regulate transcription via three major pathways. The one described best, transactivation, requires receptor dimerization and binding to cis-activating palindromic glucocorticoid response elements (GREs) located in the promoter region of target genes (13, 14) . So far no response elements specific for the mineralocorticoid receptor have been described. Another way of gene regulation is the binding to negative glucocorticoid response elements (nGREs), leading to transrepression (15) . The third one is transrepression by inactivation of transcription factors such as AP-1, NF-kB and NF-AT, which seems to be the main mechanism in the anti-inflammatory action of natural and synthetic glucocorticoids (1, 16, 17) . Additional extragenomic effects have been described both for mineralo-and gluco-corticoids (18 -20) .
The scientific origin of many data describing the agonistic properties of widespread synthetic GCs is elusive. As they are based on several in vivo and in vitro tests under varying conditions and with different parameters measured (4, 21 -28) , it is almost impossible to compare them in a reliable way. Our aim was to evaluate the glucocorticoid potencies of different therapeutically used steroids systematically by employing a human GR (hGR)-dependent transactivation assay in CV-1 cells. In a second step, we intended to compare their mineralocorticoid potencies in an equivalent assay differing from the first one merely by the presence of the human MR (hMR) instead of the hGR. To complement the latter transactivation data, we investigated their prerequisite, the steroid binding to the hMR. The intention of this approach was to facilitate the optimizing of long-term steroid therapies and the prediction of GC and MC properties of future synthetic steroids.
Materials and methods

Steroids
The steroids were puchased from Bristol Myers Squibb GmbH (Regensburg, Germany), Glaxo Research and Development (Stevenage, UK), Merck, MMDRI-Lepetit Research Center (Gerenzano, Italy), Paesel and Lorei (Hannover, Germany), Schering (Berlin, Germany), Sigma Chemical (St Louis, MO, USA) ( Table 1) . For a better understanding of the formulas, see Fig. 1 .
Plasmids
pRShMR and pRShGR were gifts from Prof. R Evans (The Salk Institute, La Jolla, CA, USA). The plasmids contain the coding sequence for the hMR and the hGRa respectively, under the control of the Rous sarcoma virus long terminal repeat and the SV40 origin of replication. The structure of the pRShGR is identical to that of the pRShMR with the exception of the part containing the hMR coding nucleotides which has been replaced by the coding sequence of the hGRa (5, 29) .
pMMTV-Luc was kindly provided by Dr B Gellersen (Hamburg, Germany). It contains the cDNA for firefly luciferase, which catalyses a light emitting reaction on addition of the proper substrate. Transcription is controlled by glucocorticoid responsive elements present in the mouse mammary tumor virus long terminal repeat (MMTV-LTR) (30) immediately upstream from the luciferase sequence (31) .
The pRL-SV40 vector (Promega, Madison, WI, USA) causes constitutive expression of Renilla luciferase and does not require post-translational modification for activity (32) . It served as an internal standard to normalize firefly luciferase light emission measurements with regard to transfection efficiency and the number of cells in each well.
Cell culture, transfection and transactivation assay
The transfections and transactivation assays were carried out in CV-1 cells (african green monkey kidney . The transactivational response was determined as the ratio of firefly to Renilla luciferase activity normalized to the maximum activity of reference substances: dexamethasone for GR-and aldosterone for MR-mediated transactivation. The resulting graphs start at a baseline effect and asymptotically approach individual maximal effects (Fig. 2 ). To characterize these curves, we calculated the concentration (EC 50 ) at which 50% of the asymptotical maximum effect (E max ) was achieved by iterative nonlinear regression using the Prism software (Version 3.02) from GraphPad (San Diego, CA, USA). Differences in EC 50 values were tested for significance with the same software by means of a modified two-tailed t-test.
Coupled cell-free transcription and translation of hMR
Expression of hMR from the plasmid pchMR (kindly provided by Prof. M Rafestin-Oblin, Institut National de la Sante et de la Recherche Medicale, Paris, France) containing the hMR cDNA (34) was performed in a coupled rabbit reticulocyte lysate system for transcription and translation (TNT R from Promega, Madison, WI, USA). T7 RNA polymerase was used for synthesis of hMR mRNA which was translated to hMR during incubation of 90 min at 30 8C according to the manufacturer's instruction.
Steroid-binding competition at the hMR
H-aldosterone (5 nM) was incubated in the absence or presence of unlabelled aldosterone (5 mM) for determination of specific and nonspecific ligand binding. Different unlabelled steroids were tested for competition at the hMR in increasing concentrations (10 211 to 10 26 M) as duplicates. The incubation volume was 25 ml, and steroids were dissolved in 12.5 ml of TEGDW buffer (20 mM Tris -HCl pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 20 mM sodium tungstate and 10% glycerol) mixed with 0.2% ethanol. 12.5 ml aliquots of reticulocyte lysate containing synthesized hMR were added to ice-cold steroid solution in TEGDW and incubated for 4 h at 4 8C for steroid binding. Unbound steroids were separated using dextrane-coated charcoal (DCC): 1 ml of 0.5% DCC in TEGDW was added to each 25 ml binding assay mixture, shaken for 7 min on ice and centrifuged at 14 000 g for 10 min at 4 8C. Aliquots of 780 ml from the supernatant were added to 10 ml of Ultima Gold solution (Packard Bioscience, Groningen, Netherlands) and analyzed in a b-counter (Winspectral, 1414 PerkinElmer, Turku, Finland). D.p.m. values were calculated online using an external standard. The affinities of the steroids to the hMR were calculated as IC 50 values by nonlinear regression with Prism (see above) assuming one site competition.
Results
To ensure that our CV-1 cell system does not contain relevant amounts of endogenous GR or MR, the transactivation activities of the two reference substances, dexamethasone and aldosterone, were measured in CV-1-cells that had not been transfected with steroid receptor expression vectors. Likewise, the system was tested for endogenous steroids by measuring the transactivation activity without prior addition of steroids but after transfection with hMR or hGR expression vectors. Neither approach led to relevant transactivation. In assays with receptor transfection, aldosterone induced half-maximal transactivation via the MR at concentrations about one order of magnitude below the EC 50 observed with dexamethasone and the GR (Fig. 2) .
All GC potencies calculated by our in vitro transactivation assay are listed in Table 2 . Based on these results, the main structural features determining GC potency are the size and the polarity of the substituent in position 6 or 16 (Table 4) . A hydrophobic residue increases GC activity of a steroid (statistically significant enhancement with 6a-methyl and 16-methylene substitution, tendency not reaching significance with 16a-and 16b-methyl and 16,17-methyloxazoline groups). The more polar 16-hydroxy substitution decreases GC potency.
The other important position for GC activity is the 11-hydroxy group, present in the glucocorticoids tested but not in aldosterone (hemiacetal form), which consequently possesses a low GC potency. The 6a-and 9a-fluorination leads to increased GC transactivation, which also applies to the D1-dehydro-configuration (in prednisolone).
6a-or 9a-fluorination and the keto configuration of the 11-hydroxy group affect the MC potencies (Table 3) qualitatively in the same way as the GC potencies (Table 4) . However, opposite to the effect observed with the GR, the D1-dehydro-configuration and the 16-methylene, 16a-methyl and 16b-methyl groups attenuate MC potency.
In binding competition experiments with the hMR (Fig. 3) , we found displacement of the ligand 3H-aldosterone decreasing in strength from 9a-fluorocortisol, 6a-fluorocortisol and cortisol to aldosterone, 6a-methylprednisolone and prednisolone (nearly the same displacement by the last three steroids), followed by dexamethasone, prednylidene, oxo-dexamethasone and cortisone. Thus, the MR affinity parallels the strength of MC agonism in our transactivation assay, with the exception of a discrepancy between the relatively weak binding of aldosterone (e.g. compared with cortisol) and its high transactivational potency.
Discussion
The traditional ways to measure GC and MC potencies of steroids refer to anti-inflammatory (rat ear edema test, McKenzie vasoconstriction test) or metabolic (liver glycogen assay) effects and sodium retention. Depending on the testing conditions, absolute potency values vary considerably. It is therefore extremely difficult, if not impossible, to arrange the individual results from different research groups to compile a comprehensive list (4, 21 -28) . Considering these very complex in vivo actions, we tried to focus on a level that allows the comparison of several steroids in vitro. However, even though the results from our transactivation assays with the GR and MR were surprisingly congruent with GC and MC potency lists contained in most standard textbooks of medicine and pharmacology (see Tables 2 and 3 for comparison of relative GC and MC potencies), it is obvious that conclusions with respect to the use of GCs in humans must be drawn with caution. The GC potency of dexamethasone in vivo is reported to be slightly higher than (24, 35) or equal to (21, 23) that of betamethasone. We observed a moderately higher transactivation activity of betamethasone compared with dexamethasone. 9a-fluorocortisol, 6a-methylprednisolone, desacetyldeflazacort and prednisolone all showed similar EC 50 values of approximately 2 to 7 £ 10 29 M in our GR assay, in an order that corresponds well to their in vivo potencies (4).
The comparison of the in vitro activities of deflazacort and desacetyldeflazacort with their in vivo GC potencies illustrates the activation of the prodrug deflazacort to desacetyldeflazacort in vivo.
Aldosterone, the physiological MC, is often described as possessing no GC activity at all. However, we found GR-mediated transactivation by aldosterone, but at concentrations relative to cortisol that are not even reached in primary hyperaldosteronism (36, 37) . Table 4 Different functional groups and their effects on the glucocorticoid (GC) and mineralocorticoid (MC) activity of a steroid " Enhancement or # attenuation of the glucocorticoid (upper part) or mineralocorticoid activity by functional groups (left column). Compared are compounds without the corresponding group (column second from the right) with those with the group (right column). Differences are significant (p , 0.05), except for ( " ) or ( # ) which show trends (p . 0.05). The low receptor binding of cortisone and prednisone is well known (26, 35) . The biological activity of these substances depends on first pass activation by hepatic 11b-hydroxysteroid-dehydrogenase type 1 (11b-HSD1). When cortisone (or prednisone) is injected in an organ without 11b-HSD1, e.g. intra-articularly, it has no biological activity. This fits well with our results for cortisone and prednisone, which also prove that our assay does not contain relevant amounts of 11b-HSD1. Progesterone was previously shown to bind to the GR (26, 35) but is said to exhibit only slight agonistic activity (38) which was not detected with our assay.
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The most noticeable incongruence is the high GC transactivation activity for prednylidene, given an in vivo potency comparable to that of prednisolone. As pharmacokinetics of prednylidene do not explain this discrepancy (39), prednylidene is a good candidate for further pharmacological investigations, e.g. concerning the relation between its transrepression and transactivation activity (17, 40, 41) . The weak transactivation by triamcinolone corresponds to its relatively low receptor affinity (24) , but contrasts with its high in vivo potency.
In summary, the influence of a 6a-and 16a-methyl substitution, 9a-fluorination, 16a-hydroxylation and the D1-dehydro-configuration on transactivation by synthetic GCs via the GR (Table 4) show good correspondence to in vivo data (4) . In addition, 6a-fluorination, 16-methylene and 16,17-methyloxazoline groups increase GC potency in vitro.
Published comparative data on MC potencies are more scanty. Besides transactivation, MC activity in target tissues depends on prereceptor metabolism by 11b-hydroxysteroid-dehydrogenase type 2 (11b-HSD2), which is co-localized with the MR and inactivates 11-hydroxysteroids to their corresponding 11-oxoderivatives (39) . The very poor MR-mediated transactivation (Table 3) of cortisone is a well-known necessity for this gatekeeper effect of the 11b-HSD2, which is also true for prednisone.
The 6a-methyl group has been reported to diminish MC activity in vivo (4, 23). We could not find such an effect in vitro, neither in transactivation (Tables 3 and 4 ) nor in binding experiments (Fig.  3) . Therefore the reduced in vivo MC activity of 6a-methylprednisolone compared with prednisolone may primarily be due to its enhanced GC activity (Tables 2 and 4 ) resulting in different equivalent dosages 2 4 mg of 6a-methylprednisolone versus 5 mg of prednisolone 2 used for pharmacological GC therapy (4, 21, 23, 25) .
The prodrug deflazacort exhibits a very low MC activity. At first sight, this seems to support the opinion that deflazacort causes less MC side effects than some of the older steroids. However, as Assandri et al. could show (42) , deflazacort is rapidly metabolized to desacetyldeflazacort which does possess some MC activity in our assay.
Complementary to the transactivation assays, binding to the MR was analyzed (see Fig. 3 and Table 5 ). For most steroids tested, the binding affinity was compatible with the transactivation activity measured (Table 3) . One remarkable discrepancy is the MR binding affinity of cortisol being very close to that of aldosterone, while cortisol proved to be the weaker mineralocorticoid in terms of transactivation. Similar binding of aldosterone and cortisol to the hMR, but more potent transactivation via the MR by aldosterone, was described by Rupprecht et al. (38) and Hellal-Lévy et al. (43) . The latter group showed that although the affinities for the MR are nearly the same, aldosterone dissociates much slower than cortisol from this receptor, and they assumed different induction of conformation changes of the MR by these ligands. Similarly, almost identical MR binding of aldosterone, 6a-methylprednisolone and prednisolone contrasts with our transactivation experiments (Table 3 ) and in vivo data (4). In general, one can conclude that receptor binding is only a prerequisite of the much more complex process of transactivation, and that a correlation between binding affinities and transactivation properties cannot be assumed a priori for all steroids. A good example for this notion is progesterone (Table 3) , which has been shown to possess high affinity to the hMR but causes only minor transactivation at the MR (33, 38) and acts as an antagonist in vivo (44) .
The more selective GC transactivation activity of GCs with a 16a-methyl or 16b-methyl group and a D1-dehydro-configuration results from a significantly decreased activity via the MR and an enhanced activity via the GR (Table 4 ). The D1-dehydro-configuration in prednisolone both decreases MC transactivation and increases oxidation by 11b-HSD2 (39) . Fluorination leads to enhanced transactivation (Tables 3 and 4) and attenuated oxidation by 11b-HSD2 (39) . Therefore, the reduced MC activity in vivo of prednisolone compared with cortisol and the increased activity of fluorinated steroids is probably due both to pharmacokinetic (prereceptor metabolism) and pharmacodynamic (MC transactivation) reasons. Because some catalytic activity of 11b-HSD2 has been demonstrated in CV-1 cells (45) , an effect of this enzyme in our transactivation assay leading to a shift of EC 50 values in either direction cannot be ruled out completely. This may contribute to the weaker effect of cortisol relative to aldosterone in the MR transactivation assay. However, because the 11b-HSD2 activity in the CV-1 cells affects the ligand concentration regardless of a transfection with vectors for GR or MR, the ratio of GC to MC potency in our assay is less sensitive to prereceptor metabolism. Therefore this ratio may be a useful parameter for receptor-mediated selectivity. This is illustrated in Fig. 4 : highly selective GCs will be found in the lower right quadrant, highly selective MCs in the upper left quadrant. According to the EC 50 ratio, the most selective glucocorticoids are prednylidene, budesonide, beclomethasone and betamethasone. The most selective mineralocorticoid is the natural hormone, aldosterone.
It is important to keep in mind that the luciferase assay is an in vitro system which differs from in vivo conditions in many aspects, e.g. altered prereceptor regulation by steroid metabolizing enzymes such as 11b-HSDs (39, 46 -48) , lacking integration of the reporter gene into chromatine (11) and different concentrations of heat shock proteins, GR (49) and other transcription factors (8 -10, 14) . An important influence of the cell type used in the transactivation assay has been shown (50) . Nongenomic effects postulated both for cortisol and aldosterone (19, 51) are neither taken into account. Moreover, transrepression of genes (1, 17, 40) could not be evaluated by our approach. Therefore, additional testing with transrepression assays is required to detect possible dissociative glucocorticoid effects.
In spite of all constraints, the in vitro assay employed represents a suitable system to compare the specificity of natural and synthetic steroidal homones with regard to the human glucocorticoid and mineralocorticoid receptors. Comparing the influence of further functional groups on transactivation via the hGR and the hMR will help to understand the structure (52, 53) and functionality of the substrate binding sites in these receptors. 
